Key points from article :
Insilico's AI engine, PandaOmics, led a global team, including the University of Oslo and University of Chicago Pritzker School of Medicine, to pinpoint groundbreaking dual targets for both cancer and ageing.
They analysed transcriptomic data from healthy and tumor samples.
They identified 51 potential dual-purpose targets and validated one of them.
The validated target is histone demethylase, or KDM1A.
KDM1A extends lifespan in a simple model organism and has anti-cancer activity.
The findings not only present a potential breakthrough but emphasise the crucial role of AI in navigating the complexities of age-related diseases and cancer.
